Korro Bio (KRRO) Long-Term Investments (2021 - 2026)
Korro Bio's (KRRO) quarterly Long-Term Investments came in at $43.1 million in Q1 2026, up 79.22% YoY from $24.0 million in Q1 2025, and up 329.5% on a QoQ basis from $10.0 million in Q4 2025.
Korro Bio (KRRO) Long-Term Investments (2021 - 2026) Analysis & Trends
Korro Bio (KRRO) has 5 years of Long-Term Investments data on file, last reported at $43.1 million in Q1 2026.
- Quarterly Long-Term Investments rose 79.22% year-over-year to $43.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.1 million (up 79.22% YoY) and the FY2025 annual result came in at $10.0 million, down 72.86% from the prior year.
- Long-Term Investments grew to $43.1 million in Q1 2026, from $10.0 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $43.1 million in Q1 2026 to a low of $7.4 million in Q1 2022.
- A 4-year average of $24.1 million and a median of $24.0 million in 2025 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2025 — Long-Term Investments tumbled 72.86% — and 2026, when it surged 79.22%.
- Tracing KRRO's Long-Term Investments over 4 years: stood at $7.4 million in 2022, then surged by 398.77% to $37.0 million in 2024, then plunged by 72.86% to $10.0 million in 2025, then jumped by 329.5% to $43.1 million in 2026.
- The last three Long-Term Investments figures came in at $43.1 million (Q1 2026), $10.0 million (Q4 2025), and $10.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Korro Bio | 231.77 Mn | 116.73 Mn | - | 22.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.89 Mn |
| Mar 31, 2026 | 43.08 Mn |
| Dec 31, 2025 | 10.03 Mn |
| Sep 30, 2025 | 10.01 Mn |
| Jun 30, 2025 | 23.26 Mn |
| Mar 31, 2025 | 24.04 Mn |
| Dec 31, 2024 | 36.96 Mn |
| Sep 30, 2024 | 32.12 Mn |
| Jun 30, 2024 | 30.34 Mn |
| Mar 31, 2022 | 7.41 Mn |
| Dec 31, 2021 | 11.72 Mn |
| Sep 30, 2021 | 12.40 Mn |
| Jun 30, 2021 | 6.64 Mn |